ARK Genomic Revolution ETF (ARKG)

Look-through valuation · Theme · Expense ratio 0.75 % · ISIN US00214Q3020

ARKG ARK Genomic Revolution ETF ARKG overvalued

Holdings vs fair value −60.2 % weighted average

Quality 48/100 avg alpha quality

Expense ratio 0.75 % per year (TER)

Fund size $ 1.3B

The look-through covers 93 % of the fund by weight (26 of 30 disclosed positions valued). Unresolved positions are left out, never estimated.

Price history (since 2014)

Monthly close since 2014. Price shows performance, the valuation verdict is in the look-through above.

Top holdings

Holding	Weight	vs fair value	Quality
10X Genomics Inc TXG	7.9 %	−62.4 %	64
Tempus AI, Inc. Class A Common Stock TEM	7.7 %	−77.9 %	33
Twist Bioscience Corp TWST	7.4 %	−80.0 %	58
Personalis Inc PSNL	6.7 %	−39.6 %	44
Crispr Therapeutics AG CRSP	6.3 %	−66.8 %	28
Absci Corp ABSI	6.2 %	−80.0 %	41
Guardant Health Inc GH	4.4 %	−80.0 %	49
Eli Lilly and Company LLY	4.4 %	−65.7 %	73
Beam Therapeutics Inc BEAM	4.2 %	−83.0 %	39
Illumina Inc ILMN	4.2 %	−49.0 %	82
Natera Inc NTRA	4.0 %	−80.0 %	46
Veracyte Inc VCYT	3.0 %	−69.3 %	69
CareDx Inc CDNA	2.9 %	−66.9 %	64
Compass Pathways Plc CMPS	2.9 %	n/a	n/a
Recursion Pharmaceuticals Inc RXRX	2.7 %	−77.1 %	21
Butterfly Network Inc BFLY	2.4 %	−70.7 %	45
Nurix Therapeutics Inc NRIX	2.3 %	−16.4 %	42
Intellia Therapeutics Inc NTLA	2.3 %	+65.8 %	34
Adaptive Biotechnologies Corp ADPT	2.3 %	−26.4 %	57
Schrodinger Inc SDGR	2.0 %	+53.6 %	45
GeneDx Holdings Corp. WGS	1.7 %	−80.0 %	36
Ionis Pharmaceuticals Inc IONS	1.7 %	−78.7 %	34
Alamar Biosciences, Inc. Common Stock ALMR	1.5 %	n/a	n/a
Cerus Corporation CERS	1.4 %	−80.0 %	51
Prime Medicine, Inc. Common Stock PRME	1.3 %	−26.7 %	25

Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 30 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.

How the look-through works

An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives ARK Genomic Revolution ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.

As of: Jul 17, 2026

No investment advice, no buy or sell recommendation. The look-through is a computed summary of public fundamentals and is no substitute for your own research.